Discovery of a Potent and Selective BCL-X-L Inhibitor with in Vivo Activity
Zhi-Fu Tao, Lisa Hasvold, Le Wang, Xilu Wang, Andrew M Petros, Chang H Park, Erwin R Boghaert, Nathaniel D Catron, Jun Chen, Peter M Colman, Peter E Czabotar, Kurt Deshayes, Wayne J Fairbrother, John A Flygare, Sarah G Hymowitz, Sha Jin, Russell A Judge, Michael FT Koehler, Peter J Kovar, Guillaume Lessene Show all
ACS Medicinal Chemistry Letters | AMER CHEMICAL SOC | Published : 2014
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by Leukemia and Lymphoma Society
Awarded by Cancer Council of Victoria
Awarded by NHMRC Independent Research Institutes Infrastructure Support Scheme
This work was sponsored by AbbVie, Inc., and Genentech, a member of the Roche group. Part of this work was supported by fellowships and grants from the Australian Research Council (fellowship to P.E.C.), the National Health and Medical Research Council (NHMRC, fellowships to P.M.C.; development grant 305536 and program grants 257502, 461221, and 1016701), the Leukemia and Lymphoma Society (specialized center of research grant nos. 7015 and 7413), the Cancer Council of Victoria (fellowship to P.M.C.; grant-in-aid 461239), and the Australian Cancer Research Foundation. Infrastructure support from the NHMRC Independent Research Institutes Infrastructure Support Scheme grant no. 361646 and a Victorian State Government OIS grant are gratefully acknowledged.